February 27, 2012 / 1:22 PM / in 6 years

Valeant posts 4th-qtr profit on acquisitions

Feb 27 (Reuters) - Canadian drugmaker Valeant Pharmaceuticals International posted a fourth-quarter net profit, helped mainly by acquisitions and the growth of key dermatology brands.

For the October-December quarter, net income was $55.9 million, or 18 cents a share, compared with a net loss of $31.1 million, or 10 cents a share, a year ago.

Revenue rose 34 percent to $688.5 million.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below